FYI..PERI Did just find out they are having a 50 million dollar worth of public offering of ordinary shares..So don't jump in until you see direction this morning.
News just out EVLO Up 14% 17.50 Evelo Biosciences reports new positive data fro Phase 1b Trial of EOP-1825 in Atopic Dermatitus Market Cap 715M Float 19 M
OGEN..Up 18%..1.10..Low of .88 today News today on progress of Covi-19 Vaccine..Patients to be enrolled by Mid-Year
VUZI..Up 20%..11.21 Vuzis a leading supplier of smart glasses colloborating with Hippo Technologies to connect global surgeons and healthcare and medical education..Also to connect global surgeons and healthcare providers with vital medical networks. Market Cap 480 million Float 38 million Vanguard owns 5.5 million dollars worth of stock Over the next three months potential to grow 116% Holding 14.87-26.96 Cash 25million Cash Burn 16million Short term assets exceed Short and Long term liabilities Assets 42 million..Debt 3 million
News out this morning from Switzerland ADXN..10.55..Addex Therapeutics Addex received IND approval to start a Phase 2a Clinical Study in Epilepsy Some very mixed reviews on Addex..Some strong sell indicators On the bright side...VERY..LOW..FLOAT 2.39 million Short term assets exceed Short and Long term liabilities Cash 32 million can cover Cash Burn of 9 million at least for a year Assets 21 million Debt 292K
Pre-Market..ECOR..Electrocore..UP 19%..2.95 Tuesday talked about establishment of HCPSC code for non-invasive vagus nerve stimulation ECOR is a Medical Device Company Market Cap 112 million..Float 34 million Vanguard owns 1.2 million worth of shares Negative Cash of 25 million can't cover Cash Burn this year of 26 millionPositive overall assets 37 milllion Debt3 million Short term assets exceed short and long term liabilities Projected 81% growth compared to Industry average of 14% Establishing a Hammer Candle StockTA Bullish Short and Long..A Barget Strong Buy Before News Median Target Price of 3.70
Under the radar ATOS..Up 16% this morning..1.80 Very Low Float of 7 million Atossa has two programs to treat Covid-19 Covid-19 Hope Program uses AT-H201 for severely ill patients to improve lung function AT-301 Nasal Spray for at-home use immediately following diagnosis of Covid to slow down infection Median Target price 5.00
News just out SIRC...3005 Solar Integrated Roofing just completed Acquisition of Southern California Residential Solar Installer Enerev targeting an additional $2 million per month
News out late yesterday AUPH..Aurinia Pharmaceuticals..Closed 14.86 Late yesterday FDA approved AUPH..Lupkynis TM for Adult patients with Active Lupus Nephritis More Bearish Ratings than Buy...But caveat being before last night Market Cap 1.87 Billion..Owned by 199 Financial Institutions..Leader being Healthcore Management holding 130 Million worth Short term assets of 411 million exceed short term liabilities of 23 million and long term liabilities of 39 million Cash 392 million Cash Burn 121 million Return on Equity forecast to be 55% in four years Revenue expected to grow 1,100 % per year Assets 461 million Debt 8 million 52 week low 9.83..High 20.47 A Tip Ranks Strong Buy with Target price of 25.40
At the right price you might find Gold BMIX..Up 73% Friday .0076 On January 4 announced receivership of two additional mineral claims..Company focused on hard-rock lithium. Brazil Minerals owns projects in titanium, lithium and rare earths..also a stake in Jupiter Gold and several mining projects underway for diamond and gold. Could find little fundamental info..Low Market Cap of 15m outrageous high float Low last week .0018...High .0091 StockTA.Bullish short and long and a Barchart Strong Buy Now watch if it dips back down..002-0025 might be your Gold Nugget
ATOS..Up 24% Pre-Market..2.32 Clinical Stage Pharm Company ..Therapeutics for treatment of breast cancer Low Float 7 million Short term assets exceed Short and Long term liabilities Debt 31K..Assets 11 million Median Target Price 5.00
VYNE..Up Pre-Market 65%..3.10 Vyne Therapeutics a Bio-Pharm..Treatment of dermatological diseases Pipeline includes Amseeq and Zilxi Short term assets exceed both short and long term liabilities A Negative Cash Burn exceeds Cash Market Cap 315 million..Owned by 141 Institutions Holding 51% of shares Revenue growth of 128% per year Median Target price 5.50
Another appearance as Pre-Market winner VTGN..Up 30%..2.88 Treats diseases of central nervous system Viewed Undervalued Short term assets exceeds both Short and Long term liabilities Cash exceeds Cash Burn Projected 61% revenue growth Debt 4 million Assets 20 million Median Target Price 5.00..Over the weekend Alpha sais patience could lead to double present Target Price
News just out RLFTF...4821 Relief Therapeutics and Acer Therapeutics sign agreement for Worldwide Development of Acer-001 treament of Urea Cycle Disorders and Maple Syrup Disease.. ACER Up pre-market on news.
News Just Out UBS..14.53 Just reported it"s highest annual pre-tax profit of post financial crisis. 4th quarter results of 1.7 Billion Doubling analysts estimates of 900 Million
